Skip Navigation

Important News

Back to Index

SHP Pharmacy Updates - effective 1/3/2012

As of January 3, 2012, the growth hormones, Nutropin®, Nutropin AQ ®, Nutropin AQ NuSpin®, Saizen®, Valtropin®, Accretropin®, and Zorbtive®, will become non-preferred medications. In addition to ensuring that the clinical indication for use meets the State Health Plan's conditions for coverage, these medications will also be subject to step therapy.

Growth Hormone Specialty Medication - Step Therapy Program

As of January 3, 2012, all prescriptions for Travatan Z® will require a coverage review. The preferred glaucoma medications latanoprost (Xalatan®) and Lumigan® will continue to be covered without a review.

Glaucoma Agents Step Therapy Program

Beginning January 3, 2012 (and in addition to existing coverage criteria), new users of interferon beta-1a (Rebif®) and interferon beta-1b (Extavia®) must have tried and been intolerant to or failed treatment with either interferon beta-1b (Betaseron®), interferon beta-1a (Avonex®), or glatiramer acetate (Copaxone®).

Multiple Sclerosis Specialty Medication Step Therapy Program